Loading patent…
AssigneeMedImmune, LLC
InventorsKoustubh RANADE, Brandon W. HIGGS, Rajiv G. RAJA, Philip Z. BROHAWN, Han SI, Michael A. KUZIORA
Estimating the term…
The disclosure generally relates to methods for treating non-small cell lung cancer patients based on use of blood-based tumor mutation burden to predict overall survival in patients treated with durvalumab, tremelimumab, and/or a chemotherapy agent. The disclosure also relates to methods for treating non-small cell lung cancer patients based on identification of mutations in circulating tumor DNA associated with sensitivity or resistance to immunotherapy.
A method of treating non-small cell lung cancer (NSCLC) in a patient having a tumor mutational burden (TMB) that is ≥12 mutations/megabase, comprising administering durvalumab and tremelimumab to the patient.
A method of predicting success of a cancer treatment in a patient in need thereof, comprising determining the patient's tumor mutational burden (TMB), wherein a TMB that is ≥12 mutations/megabase predicts success of the treatment.
Dependencies are inferred from the claim text.